Heron Therapeutics Inc
HRTX
查看详细走势图
1.260USD
+0.050+4.13%
收盘 02/06, 16:00（美东）报价延迟15分钟
230.99M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.13%
5天
-4.55%
1月
+3.28%
6月
-30.39%
今年开始到现在
-3.08%
1年
-29.61%
查看详细走势图
TradingKey Heron Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Heron Therapeutics Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名62/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价4.50。中期看，股价处于上升通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Heron Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Heron Therapeutics Inc亮点
亮点风险
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. It creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.
业绩高增长
公司营业收入稳步增长，连续3年增长34.00%
估值合理
公司最新PE估值-15.02，处于3年历史合理位
机构加仓
最新机构持股155.38M股，环比增加2.54%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值191.71K
活跃度增加
近期活跃度增加，过去20天平均换手率0.01
分析师目标
根据
4
位分析师
买入
评级
4.500
目标均价
+271.90%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Heron Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Heron Therapeutics Inc简介
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. It creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.
公司代码HRTX
公司Heron Therapeutics Inc
CEOCollard (Craig Alexander)
网址https://www.herontx.com/
相关品种
